115 related articles for article (PubMed ID: 9357532)
1. Constrained corticotropin-releasing factor antagonists with i-(i + 3) Glu-Lys bridges.
Miranda A; Lahrichi SL; Gulyas J; Koerber SC; Craig AG; Corrigan A; Rivier C; Vale W; Rivier J
J Med Chem; 1997 Oct; 40(22):3651-8. PubMed ID: 9357532
[TBL] [Abstract][Full Text] [Related]
2. Constrained corticotropin-releasing factor (CRF) agonists and antagonists with i-(i+3) Glu-Xaa-DXbb-Lys bridges.
Koerber SC; Gulyas J; Lahrichi SL; Corrigan A; Craig AG; Rivier C; Vale W; Rivier J
J Med Chem; 1998 Dec; 41(25):5002-11. PubMed ID: 9836618
[TBL] [Abstract][Full Text] [Related]
3. Minimal-size, constrained corticotropin-releasing factor agonists with i-(i+3) Glu-Lys and Lys-Glu bridges.
Rivier J; Lahrichi SL; Gulyas J; Erchegyi J; Koerber SC; Craig AG; Corrigan A; Rivier C; Vale W
J Med Chem; 1998 Jul; 41(14):2614-20. PubMed ID: 9651165
[TBL] [Abstract][Full Text] [Related]
4. Astressin analogues (corticotropin-releasing factor antagonists) with extended duration of action in the rat.
Rivier J; Gulyas J; Corrigan A; Martinez V; Craig AG; Taché Y; Vale W; Rivier C
J Med Chem; 1998 Dec; 41(25):5012-9. PubMed ID: 9836619
[TBL] [Abstract][Full Text] [Related]
5. Corticotropin releasing factor (CRF) agonists with reduced amide bonds and Ser7 substitutions.
Cervini L; Theobald P; Corrigan A; Craig AG; Rivier C; Vale W; Rivier J
J Med Chem; 1999 Feb; 42(4):761-8. PubMed ID: 10052982
[TBL] [Abstract][Full Text] [Related]
6. Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor.
Gulyas J; Rivier C; Perrin M; Koerber SC; Sutton S; Corrigan A; Lahrichi SL; Craig AG; Vale W; Rivier J
Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10575-9. PubMed ID: 7479843
[TBL] [Abstract][Full Text] [Related]
7. Constrained corticotropin releasing factor antagonists (astressin analogues) with long duration of action in the rat.
Rivier JE; Kirby DA; Lahrichi SL; Corrigan A; Vale WW; Rivier CL
J Med Chem; 1999 Aug; 42(16):3175-82. PubMed ID: 10447963
[TBL] [Abstract][Full Text] [Related]
8. Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies.
Cervini LA; Donaldson CJ; Koerber SC; Vale WW; Rivier JE
J Med Chem; 1998 Feb; 41(5):717-27. PubMed ID: 9513600
[TBL] [Abstract][Full Text] [Related]
9. Conformationally restricted competitive antagonists of human/rat corticotropin-releasing factor.
Miranda A; Koerber SC; Gulyas J; Lahrichi SL; Craig AG; Corrigan A; Hagler A; Rivier C; Vale W; Rivier J
J Med Chem; 1994 May; 37(10):1450-9. PubMed ID: 8182703
[TBL] [Abstract][Full Text] [Related]
10. A single-point slight alteration set as a tool for structure-activity relationship studies of ovine corticotropin releasing factor.
Beyermann M; Fechner K; Furkert J; Krause E; Bienert M
J Med Chem; 1996 Aug; 39(17):3324-30. PubMed ID: 8765516
[TBL] [Abstract][Full Text] [Related]
11. Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists.
Rivier J; Gulyas J; Kirby D; Low W; Perrin MH; Kunitake K; DiGruccio M; Vaughan J; Reubi JC; Waser B; Koerber SC; Martinez V; Wang L; Taché Y; Vale W
J Med Chem; 2002 Oct; 45(21):4737-47. PubMed ID: 12361401
[TBL] [Abstract][Full Text] [Related]
12. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor.
Vaughan J; Donaldson C; Bittencourt J; Perrin MH; Lewis K; Sutton S; Chan R; Turnbull AV; Lovejoy D; Rivier C
Nature; 1995 Nov; 378(6554):287-92. PubMed ID: 7477349
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and relative potencies of new constrained CRF antagonists.
Hernandez JF; Kornreich W; Rivier C; Miranda A; Yamamoto G; Andrews J; Taché Y; Vale W; Rivier J
J Med Chem; 1993 Oct; 36(20):2860-7. PubMed ID: 8411001
[TBL] [Abstract][Full Text] [Related]
14. An optimized solid phase synthesis strategy--including on-resin lactamization--of astressin, its retro-, inverso-, and retro-inverso isomers as corticotropin releasing factor antagonists.
Rijkers DT; den Hartog JA; Liskamp RM
Biopolymers; 2002 Feb; 63(2):141-9. PubMed ID: 11787002
[TBL] [Abstract][Full Text] [Related]
15. Importance of pituitary and brain receptors for corticotrophin-releasing factor in modulating alcohol-induced ACTH secretion in the rat.
Rivier C; Rivier J; Lee S
Brain Res; 1996 May; 721(1-2):83-90. PubMed ID: 8793087
[TBL] [Abstract][Full Text] [Related]
16. Single point D-substituted corticotropin-releasing factor analogues: effects on potency and physicochemical characteristics.
Rivier J; Rivier C; Galyean R; Miranda A; Miller C; Craig AG; Yamamoto G; Brown M; Vale W
J Med Chem; 1993 Oct; 36(20):2851-9. PubMed ID: 8411000
[TBL] [Abstract][Full Text] [Related]
17. Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism.
Dautzenberg FM; Wille S
Regul Pept; 2004 May; 118(3):165-73. PubMed ID: 15003833
[TBL] [Abstract][Full Text] [Related]
18. Effect of lysine side chain length on intra-helical glutamate--lysine ion pairing interactions.
Cheng RP; Girinath P; Ahmad R
Biochemistry; 2007 Sep; 46(37):10528-37. PubMed ID: 17718542
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological comparison of two corticotropin-releasing factor antagonists: in vivo and in vitro studies.
Curtis AL; Grigoriadis DE; Page ME; Rivier J; Valentino RJ
J Pharmacol Exp Ther; 1994 Jan; 268(1):359-65. PubMed ID: 8301577
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats.
Menzaghi F; Howard RL; Heinrichs SC; Vale W; Rivier J; Koob GF
J Pharmacol Exp Ther; 1994 May; 269(2):564-72. PubMed ID: 8182523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
